Get Axsome Therapeutics alerts:Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) – Stock analysts at B. Riley issued their Q3 2025 earnings per share (EPS) estimates for shares of Axsome Therapeutics in a research report issued on Tuesday, September 30th. B. Riley also issued estimates for Axsome Therapeutics’ Q4 2025 earnings at ($1.07) EPS, FY2025 earnings at ($4.07) EPS, FY2026 earnings at $0.60 EPS, FY2027 earnings at $8.00 EPS, FY2028 earnings at $17.66 EPS and FY2029 earnings at $24.58 EPS. Axsome Therapeutics Stock Up 0.3%Shares of Axsome Therapeutics stock opened at $120.30 on Friday. Axsome Therapeutics Company Profile(Get Free Report)Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. Recommended StoriesReceive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.